The Andalusian Agency for Health Technology Assessment assessed transcranial Doppler ultrasonography for treatment of acute ischemic stroke

26

Jan 2018

Committee of Benefits, Assurance and Financing commissioned the Andalusian Agency for Health Technology Assessment (AETSA) to assess application of transcranial Doppler ultrasonography in patients with acute ischemic stroke within the annual work plan.

In the end of November, AETSA published final report with results of evaluation. The aim of this work was to evaluate the efficacy and safety of this procedure in adjunction to treatment with intravenous recombinant tissue plasminogen activator and its possible ability to increase efficacy of intravenous recombinant tissue plasminogen activator.

For this purpose, the systematic literature review was performed. Identified evidence regarding mortality, recovery and recanalization were considered as insufficient to make a final conclusion about efficacy of transcranial Doppler ultrasonography in adjunction to intravenous recombinant tissue plasminogen activator in comparison to treatment with intravenous recombinant tissue plasminogen activator alone. Furthermore, safety outcomes were discordant in relation to sonothrombolysis (symptomatic intracerebral haemorrhage).

Additionally, authors of the report proposed several lines of future research that could generate evidence that would help decision-making in clinical practice. Thus, randomized controlled study, non-randomized controlled and cohort studies were considered appropriate to define efficacy and safety of procedure in ideal and real clinical practice. Outcomes that should be assessed within clinical studies as well as conditions for use of devices were also proposed.

See full-text report in Spanish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more